MEDBOX | Toolbox Immunization Guidelines

Atualização das recomendações provisórias da OMS sobre a vacinação contra COVID-19 de gestantes e lactantes, 2 de junho de 2021

Pan American Health Organisation PAHO (2021) C_WHO

Tags: Vacinação, COVID-19, Brazil, Lactação, vacinas,

Source: https://iris.paho.org/bitstream/handle/1

World Health Organization WHO (2021) C_WHO

Tags: vaccine, COVID-19, expiry, guideline,

Source: https://apps.who.int/iris/bitstream/hand

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (‎TTS)‎ following vaccination to prevent coronavirus disease (‎COVID-19)‎: interim guidance, 19 July 2021

World Health Organization WHO (2021) C_WHO

Tags: COVID-19, side effects, vaccination, thrombocytopenic disorder,

Source: https://apps.who.int/iris/bitstream/hand

World Health Organization WHO (2021) C_WHO

Interim Guidance, 12 July 2021; This tool was developed to assess present and surge capacities for the treatment of COVID-19 in health facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to identify areas that need further attention to enable the facility to respond effectively to the pandemic. The tool encompasses key components that are essential to managing COVID-19 in a hospital setting, including: health workforce (numbers, absences, COVID-19 infections, staff vaccinated for COVID-19 health workforce management, training and support); medicines and medical supplies for management of COVID-19; IPC capacities (protocols, safety measures, guidelines) and the availability of personal protective equipment (PPE) for staff; diagnostic testing, imaging and patient monitoring devices and supplies medical equipment for management of COVID-19, including O2 administration; COVID-19 vaccine readiness ; beds and space capacity

Tags: essential health services, COVID-19, health capacity, assesment, diagnostics, Vaccines, therapeutic, hospital readiness,

Source: https://apps.who.int/iris/rest/bitstream

COVID-19 vaccination (Western Cape Edition)

Wesern Cape Government, South Africa (2021) CC

24 May 2021; Guidance for vaccinators on how to store, prepare, draw up and administer COVID-19 vaccines Updated May 2021 · Western Cape Edition Practical Approach to Care Kit: Vaccine

Tags: Vaccination, COVID-19, South Africa, Health Workers,

Source: https://knowledgetranslation.co.za/downl

Kamps, B.S.; Camp, R. and C. Hoffmann (2021) CC

Tags: SARS-CoV-2, research, Scientific Updates, clinical management, transmission, infection control, reference guide, vaccine, virus variants, Prevention, schools, workplace,

Source: https://amedeo.com/CovidReference06.pdf

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

World Health Organization WHO (2021) C_WHO

Interim guidance, first issued 8 January 2021, updated 15 June 2021 Available in Arabic, Chinese, English, French, Russian and Spanish here: https://apps.who.int/iris/handle/10665/341786

Tags: Vaccination, COVID-19, SARS-CoV-2, mRNA, strategy, recommendations, biontech, pfizer, Comirnaty,

Source: https://apps.who.int/iris/bitstream/hand

Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine

World Health Organization WHO (2021) C_WHO

These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. This document has been updated: Version 15 June 2021

Tags: vaccine, johnson&Johnson, recommendations, approval, COVID-19, SARS-CoV-2, vector-basierter Impfstoff,

Source: https://apps.who.int/iris/rest/bitstream

Vygen-Bonnet S, Koch J, Bogdan C, et al. (2021) C1

Epidemiologisches Bulletin 23 | 2021 10. Juni 2021. Die STIKO empfiehlt die Impfung gegen COVID-19 mit einem der beiden zugelassenen mRNA-Impfstoffe (Comirnaty von BioNTech/Pfizer, COVID-19-Vaccine von Moderna) oder einer der beiden zugelassenen Vektor-basierten Impfstoffe (Vaxzevria von AstraZeneca, COVID-19 Vaccine Janssen von Janssen-Cilag International). Wie das Epidemiologische Bulletin 23/2021 ausführt, empfiehlt die STIKO bei Kindern und Jugendlichen mit Vorerkrankungen aufgrund eines anzunehmenden erhöhten Risikos für einen schweren Verlauf der COVID-19-Erkrankung eine Impfung mit dem mRNA-Impfstoff Comirnaty (BioNTech/Pfizer). Der Einsatz von Comirnaty bei Kindern und Jugendlichen im Alter von 12-17 Jahren ohne Vorerkrankungen wird derzeit nicht allgemein empfohlen, ist aber nach ärztlicher Aufklärung und bei individuellem Wunsch und Risikoakzeptanz möglich.ng unterhalb dieser Altersgrenze bleibt indes nach ärztlicher Aufklärung und bei individueller Risikoakzeptanz durch die impfwillige Person möglich

Tags: Impfungen, COVID-19, Strategie, Verteilung, Ethik, Risikogruppen, Priorisierung, Deutschland, mRNA, vector-basierter Impfstoff, Astra Zeneca, Moderna, pfizer, Risiko, Sinusvenenthrombosen, Zweitimpfung, johnson&Johnson, pediatrics, Children, Adolescents,

Source: https://www.rki.de/DE/Content/Infekt/Epi

Vygen-Bonnet S, Koch J, Bogdan C, et al. (2021) C1

Epidemiologisches Bulletin 19 | 2021 12.Mai 2021. Auf Basis der derzeit verfügbaren, allerdings noch begrenzten Evidenz und unter Berücksichtigung der gegenwärtigen pandemischen Lage empfiehlt die STIKO, Vaxzevria und COVID-19 Vaccine Janssen für Personen im Alter ≥60 Jahren zu verwenden. Der Einsatz von Vaxzevria für eine 1. oder 2. Impfstoffdosis und der COVID-19 Vaccine Janssen als einmalige Impfung unterhalb dieser Altersgrenze bleibt indes nach ärztlicher Aufklärung und bei individueller Risikoakzeptanz durch die impfwillige Person möglich

Source: https://www.rki.de/DE/Content/Infekt/Epi

	Atualização das recomendações provisórias da OMS sobre a vacinação contra COVID-19 de gestantes e lactantes, 2 de junho de 2021 Pan American Health Organisation PAHO (2021) C_WHO View PDF(0) Download (0) Add to my MEDBOX Tags: Vacinação, COVID-19, Brazil, Lactação, vacinas, Source: https://iris.paho.org/bitstream/handle/1
	Guidance on utilization of COVID-19 vaccines before the date of expiry, 19 July 2021 World Health Organization WHO (2021) C_WHO View PDF(0) Download (0) Add to my MEDBOX Tags: vaccine, COVID-19, expiry, guideline, Source: https://apps.who.int/iris/bitstream/hand
	Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (‎TTS)‎ following vaccination to prevent coronavirus disease (‎COVID-19)‎: interim guidance, 19 July 2021 World Health Organization WHO (2021) C_WHO View PDF(0) Download (0) Add to my MEDBOX Tags: COVID-19, side effects, vaccination, thrombocytopenic disorder, Source: https://apps.who.int/iris/bitstream/hand
	Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19 World Health Organization WHO (2021) C_WHO View PDF(15) Download (104) Add to my MEDBOX Interim Guidance, 12 July 2021; This tool was developed to assess present and surge capacities for the treatment of COVID-19 in health facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to identify areas that need further attention to enable the facility to respond effectively to the pandemic. The tool encompasses key components that are essential to managing COVID-19 in a hospital setting, including: health workforce (numbers, absences, COVID-19 infections, staff vaccinated for COVID-19 health workforce management, training and support); medicines and medical supplies for management of COVID-19; IPC capacities (protocols, safety measures, guidelines) and the availability of personal protective equipment (PPE) for staff; diagnostic testing, imaging and patient monitoring devices and supplies medical equipment for management of COVID-19, including O2 administration; COVID-19 vaccine readiness ; beds and space capacity Tags: essential health services, COVID-19, health capacity, assesment, diagnostics, Vaccines, therapeutic, hospital readiness, Source: https://apps.who.int/iris/rest/bitstream
	COVID-19 vaccination (Western Cape Edition) Wesern Cape Government, South Africa (2021) CC View PDF(0) Download (0) Add to my MEDBOX 24 May 2021; Guidance for vaccinators on how to store, prepare, draw up and administer COVID-19 vaccines Updated May 2021 · Western Cape Edition Practical Approach to Care Kit: Vaccine Tags: Vaccination, COVID-19, South Africa, Health Workers, Source: https://knowledgetranslation.co.za/downl
	COVID Reference 2021.6 EN Kamps, B.S.; Camp, R. and C. Hoffmann (2021) CC View PDF(126) Download (125) Add to my MEDBOX 6th edition 13 January 2021 CR 2021.6.10, uploaded on 27 May 2021 Find eight editions: Deutsch \| English \| Español \| Français \| Italiano \| Português \| Tiếng Việt \| Türkçe https://covidreference.com/downloa Tags: SARS-CoV-2, research, Scientific Updates, clinical management, transmission, infection control, reference guide, vaccine, virus variants, Prevention, schools, workplace, Source: https://amedeo.com/CovidReference06.pdf
	Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing World Health Organization WHO (2021) C_WHO View PDF(8) Download (5) Add to my MEDBOX Interim guidance, first issued 8 January 2021, updated 15 June 2021 Available in Arabic, Chinese, English, French, Russian and Spanish here: https://apps.who.int/iris/handle/10665/341786 Tags: Vaccination, COVID-19, SARS-CoV-2, mRNA, strategy, recommendations, biontech, pfizer, Comirnaty, Source: https://apps.who.int/iris/bitstream/hand
	Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine World Health Organization WHO (2021) C_WHO View PDF(1) Download (1) Add to my MEDBOX These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. This document has been updated: Version 15 June 2021 Tags: vaccine, johnson&Johnson, recommendations, approval, COVID-19, SARS-CoV-2, vector-basierter Impfstoff, Source: https://apps.who.int/iris/rest/bitstream
	Beschluss der STIKO zur 6. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Vygen-Bonnet S, Koch J, Bogdan C, et al. (2021) C1 View PDF(5) Download (1) Add to my MEDBOX Epidemiologisches Bulletin 23 \| 2021 10. Juni 2021. Die STIKO empfiehlt die Impfung gegen COVID-19 mit einem der beiden zugelassenen mRNA-Impfstoffe (Comirnaty von BioNTech/Pfizer, COVID-19-Vaccine von Moderna) oder einer der beiden zugelassenen Vektor-basierten Impfstoffe (Vaxzevria von AstraZeneca, COVID-19 Vaccine Janssen von Janssen-Cilag International). Wie das Epidemiologische Bulletin 23/2021 ausführt, empfiehlt die STIKO bei Kindern und Jugendlichen mit Vorerkrankungen aufgrund eines anzunehmenden erhöhten Risikos für einen schweren Verlauf der COVID-19-Erkrankung eine Impfung mit dem mRNA-Impfstoff Comirnaty (BioNTech/Pfizer). Der Einsatz von Comirnaty bei Kindern und Jugendlichen im Alter von 12-17 Jahren ohne Vorerkrankungen wird derzeit nicht allgemein empfohlen, ist aber nach ärztlicher Aufklärung und bei individuellem Wunsch und Risikoakzeptanz möglich.ng unterhalb dieser Altersgrenze bleibt indes nach ärztlicher Aufklärung und bei individueller Risikoakzeptanz durch die impfwillige Person möglich Tags: Impfungen, COVID-19, Strategie, Verteilung, Ethik, Risikogruppen, Priorisierung, Deutschland, mRNA, vector-basierter Impfstoff, Astra Zeneca, Moderna, pfizer, Risiko, Sinusvenenthrombosen, Zweitimpfung, johnson&Johnson, pediatrics, Children, Adolescents, Source: https://www.rki.de/DE/Content/Infekt/Epi
	Beschluss der STIKO zur 5. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Vygen-Bonnet S, Koch J, Bogdan C, et al. (2021) C1 View PDF(15) Download (11) Add to my MEDBOX Epidemiologisches Bulletin 19 \| 2021 12.Mai 2021. Auf Basis der derzeit verfügbaren, allerdings noch begrenzten Evidenz und unter Berücksichtigung der gegenwärtigen pandemischen Lage empfiehlt die STIKO, Vaxzevria und COVID-19 Vaccine Janssen für Personen im Alter ≥60 Jahren zu verwenden. Der Einsatz von Vaxzevria für eine 1. oder 2. Impfstoffdosis und der COVID-19 Vaccine Janssen als einmalige Impfung unterhalb dieser Altersgrenze bleibt indes nach ärztlicher Aufklärung und bei individueller Risikoakzeptanz durch die impfwillige Person möglich Tags: Impfungen, COVID-19, Strategie, Verteilung, Ethik, Risikogruppen, Priorisierung, Deutschland, mRNA, vector-basierter Impfstoff, Astra Zeneca, Moderna, pfizer, Risiko, Sinusvenenthrombosen, Zweitimpfung, johnson&Johnson, Source: https://www.rki.de/DE/Content/Infekt/Epi

About MEDBOX

MEDBOX Video Series